 Vapotherm Inc NYSE: VAPO expects FY21 revenue of at least 102 million, an increase of 17 million over the low end of previous guidance of 85 million - 91 million. Related Content: FDA Gives 510K Nod To Vapotherms Next-Gen High-Velocity Therapy. 